California will not renew $54 million contract with Walgreens over abortion pill policy

California will not renew  million contract with Walgreens over abortion pill policy


A Walgreens store in San Francisco, California, US, on Tuesday, March 7, 2023.

David Paul Morris | Bloomberg | Getty Images

California will not renew a $54 million contract with Walgreens over the drug store chain’s decision not to sell the abortion pill in some states due to legal restrictions.

“California will not stand by as corporations cave to extremists and cut off critical access to reproductive care and freedom,” Gov. Gavin Newsom said in a statement Wednesday. “California is on track to be the fourth largest economy in the world and we will leverage our market power to defend the right to choose.”

Newsom said on Monday that the state was “done” doing business with Walgreens. California used the contract to buy specialty prescription drugs for the prison system. The state is reviewing all of its business contracts with Walgreens.

Walgreens said it will sell the abortion pill, mifepristone, in any state where it is “legally permissible to do so.” Republican attorneys general in 21 states warned Walgreens in February that selling or distributing the abortion pill in their states would violate local laws.

The drug store chain told them it would not sell or mail mifepristone in their states.

The Food and Drug Administration in January allowed retail pharmacies like Walgreens to sell mifepristone so long as they become certified under an agency program that monitors how the pill is used and distributed. Walgreens and CVS have said they plan to become certified under that program.

At least 12 states have banned abortion since the Supreme Court overturned Roe v. Wade last year. Several other states have tighter restrictions on mifepristone than the FDA does.

Walgreens is also not selling the abortion pill in states like Alaska, Kansas or Montana where abortion is protected as a right under the states’ constitutions. The drug store will also not sell mifepristone in Iowa, where the state Supreme Court last year overturned state constitutional protections for abortion.

Alaska requires patients to get the pill from a doctor. In Kansas, the state had required patients to obtain the abortion pill in person from a physician, but a state court blocked that law in November. Montana’s requirement that patients visit a doctor to get mifepristone is also temporarily blocked by a court.

Join CNBC’s Healthy Returns on March 29th, where we’ll convene a virtual gathering of CEOs, scientists, investors and innovators in the health care space to reflect on the progress made today to reinvent the future of medicine. Plus, we’ll have an exclusive rundown of the best investment opportunities in biopharma, health-tech and managed care. Learn more and register today: http://bit.ly/3DUNbRo

CNBC Health & Science

Read CNBC’s latest global health coverage:



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More